1 |
EDITORIAL] Gut microbiomes and their metabolites shape human and animal health
|
Woojun Park* |
vol.56,No.3,2018 |
151-153 |
2 |
REVIEW] Intestinal microbiota and the immune system in metabolic diseases
|
Panida Sittipo1, Stefani Lobionda1, Yun Kyung Lee1*, and Craig L. Maynard2* |
vol.56,No.3,2018 |
154-162 |
3 |
REVIEW] Type 3 regulatory T cells at the interface of symbiosis
|
Joo-Hong Park1,2* and Gérard Eberl1,2* |
vol.56,No.3,2018 |
163-171 |
4 |
REVIEW] Mind-altering with the gut: Modulation of the gut-brain axis with probiotics
|
Namhee Kim, Misun Yun, Young Joon Oh, and Hak-Jong Choi* |
vol.56,No.3,2018 |
172–182 |
5 |
REVIEW] Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease
|
Jin Ah Cho1 and Daniel J.F. Chinnapen2,3,4* |
vol.56,No.3,2018 |
183–188 |
6 |
REVIEW] Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease
|
Taekil Eom1, Yong Sung Kim2, Chang Hwan Choi3, Michael J. Sadowsky4,5,6, and Tatsuya Unno1,7* |
vol.56,No.3,2018 |
189–198 |
7 |
REVIEW] The Ruminococci: key symbionts of the gut ecosystem
|
Alex J. La Reau and Garret Suen* |
vol.56,No.3,2018 |
199–208 |